Skip to content

About Biosimilars
Support
Our Products
Resources

About Biosimilars
Support
Our Products
Resources

By continuing to use this site, you agree to our use of cookies as described in our Cookie Policy.

Full Prescribing Info
Important safety info
Patient Information

Full Prescribing Info
Important safety info
Patient Information

About
Product Info & Dosing
Support & Resources
For Patients

About
Product Info & Dosing
Support & Resources
For Patients

Full Prescribing Info

FylnetraUSPI-April2025

Download PDF

IMPORTANT SAFETY INFORMATIONN

Important Safety Information

Indications and Usage

Indication: FYLNETRA is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Limitations of Use: FYLNETRA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Important Safety Information

Indications and Usage

Indications: FYLNETRA® is a leukocyte growth factor indicated to

Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Increase survival in patients acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute radiation syndrome).

Limitations of Use: FYLNETRA® is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Contraindications: Patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim products or pegfilgrastim products.

Before taking FYLNETRA®, tell your healthcare provider if you are pregnant or plan to breast feed, and if you have sickle cell disorder, kidney problems or receiving radiation therapy.

Warnings and Precautions:

Fatal splenic rupture: Patients may experience enlarged spleen which can rupture and cause death.
Acute respiratory distress syndrome (ARDS): Patients may develop fever and lung infiltrates or respiratory distress for ARDS. Discontinue FYLNETRA® in patients with ARDS.
Serious allergic reactions, including anaphylaxis: Permanently discontinue FYLNETRA® in patients with serious allergic reactions.
Fatal sickle cell crises: Serious sickle cell crises have been reported in patients with sickle cell disorders receiving FYLNETRA®. Discontinue FYLNETRA® if sickle cell crisis occurs.
Kidney injury (Glomerulonephritis): Kidney injury have been reported in patients on FYLNETRA®. Consider dose-reduction or interruption of FYLNETRA® in patients with kidney injury.
White blood cell (WBC) counts of 100 x 10⁹/L or greater have been observed in patients receiving pegfilgrastim products. Monitoring of complete blood count (CBC) during FYLNETRA® therapy is recommended.
Decreased platelet count (thrombocytopenia) has been reported in patients receiving pegfilgrastim. Monitor platelet counts.
Capillary leak syndrome has been reported after G-CSF administration, including pegfilgrastim products, and is characterized by hypotension, hypoalbuminemia, edema and hemoconcentration.
The possibility that pegfilgrastim products act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which pegfilgrastim products are not approved, cannot be excluded.
Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): Monitor patients with breast and lung cancer using FYLNETRA® in conjunction with chemotherapy and/or radiotherapy for signs and symptoms of MDS/AML.
Aortitis has been reported in patients receiving pegfilgrastim products.
Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes.

Adverse Reactions: Most common adverse reactions (≥ 5% difference in incidence compared to placebo) are bone pain and pain in extremity.

Click here for full prescribing information.

Privacy Notice
Copyright & Legal Disclaimer
Web Accessibility
Expanded Access Policy
NABP DDA Accreditation

Privacy Notice
Copyright & Legal Disclaimer
Web Accessibility
Expanded Access Policy
NABP DDA Accreditation

Linkedin X-twitter Youtube